Dogwood Therapeutics to Join Global Investment Forum
ATLANTA — Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a biotechnology company on the forefront of developing innovative treatments for pain and fatigue-related disorders, is excited to announce its participation in the prestigious H.C. Wainwright 27th Annual Global Investment Conference. This event is set to take place at the luxurious Lotte New York Palace Hotel.
Fireside Chat Details
During the conference, Greg Duncan, the Chief Executive Officer of Dogwood, will engage in a fireside chat with Sean Lee, VP of Equity Research at H.C. Wainwright. This insightful discussion is scheduled for September 5, allowing attendees to gain profound insights into Dogwood's future endeavors.
Accessing the Conference
Interested parties can tune in to a live webcast of the presentation available on-demand starting at 7:00 AM ET. Following the event, a replay of the webcast will be accessible for approximately 90 days, ensuring that all interested individuals can stay informed about Dogwood's initiatives and insights discussed.
One-on-One Meetings
Greg Duncan will also be available for one-on-one meetings throughout the conference, providing a unique opportunity for investors and stakeholders to engage directly regarding the company's strong vision and upcoming projects.
About Dogwood Therapeutics
Dogwood Therapeutics focuses on the development of new, non-opioid medications aimed specifically at treating pain and disorders associated with fatigue. With its innovative research pipeline, the company is advancing two mechanistic platforms, which include a specialized analgesic program and a treatment for viral infections.
Innovative Analgesic Solutions
At the heart of Dogwood's analgesic program is Halneuron, a groundbreaking non-opioid treatment that acts as a specific modulator of voltage-gated sodium channels, effectively reducing pain transmission. Clinical trials have shown Halneuron's potential to alleviate pain in various conditions, including cancer pain and chemotherapy-induced neuropathic pain.
Advancements in Antiviral Research
In addition to pain relief, Dogwood’s antiviral research aims to address the resurgence of dormant viruses. The company's products, IMC-1 and IMC-2, combine anti-herpes agents with celecoxib, targeting conditions like fibromyalgia and Long-COVID. IMC-1 is preparing to enter Phase 3 development, while IMC-2 has shown promising results in clinical trials.
Future Trajectory and Opportunities
Looking ahead, Dogwood is poised for significant advancements in both its analgesic and antiviral programs. With a comprehensive focus on pain management and innovative antiviral solutions, the company seeks to redefine treatment paradigms for patients suffering from complex conditions.
Stakeholder Engagement
Dogwood Therapeutics is keen to foster robust relationships with investors and the healthcare community. The company’s commitment to transparency and stakeholder communication is evident in its active participation at industry conferences.
Frequently Asked Questions
What is Dogwood Therapeutics focused on?
Dogwood is dedicated to developing non-opioid medications for pain and fatigue-related disorders.
When is the fireside chat scheduled?
The fireside chat will take place on September 5, allowing insights into company strategies.
How can one access the conference webcast?
The conference webcast will be available on-demand, starting at 7:00 AM ET, with a replay accessible for 90 days.
What clinical developments are underway?
Dogwood is progressing with clinical studies for its lead product, Halneuron, and its antiviral candidates IMC-1 and IMC-2.
How can investors connect with Dogwood?
Investors looking to engage can request one-on-one meetings during the conference with Greg Duncan via the company's investor relations.
